Serum gets DCGI nod for Phase 2 & 3 trials
India’s apex drug regulator has allowed Pune-based Serum Institute of India to conduct late-stage — Phase 2 and 3 — human trials in India for the Oxford University Covid-19 vaccine candidate. Times of India https://ift.tt/39ZeN7J